Experts discuss the importance of safe, effective topical therapies for long-term management of atopic dermatitis, ...

The FDA issued a complete response letter for SYD-101, citing insufficient evidence of effectiveness despite achieving ...

The FDA declined to approve SYD-101, a low-dose atropine formulation that would have been the first pharmaceutical treatment ...

About 32.5% of pediatric patients experienced long COVID symptoms lasting more than 1 year following acute COVID-19 infection.

Pneumonia-related mortality rates decreased among children in the United States from 1999 to 2023, particularly among infants aged less than 1 year.

While the trial met its primary endpoint, the FDA stated in its letter that the application could not be approved in its current form.

ORLANDO, Fla. — Pfizer is the only FDA-authorized vaccine for ages 12 and up, but many families want to know when a COVID-19 vaccine will be available for younger children. The FDA released ...

The FDA has expanded the approval of Yuflyma (adalimumab-aaty) and its unbranded version to include the treatment of HS in patients aged 12 years and older and UV in pediatric patients aged 2 years ...

Recognizing that half of eligible children are not enrolled in the supplementary nutrition program for women, infants, and ...